EUVIMEDOpdag EUVIMED
Crossref

Middle Meningeal Artery Lidocaine Infusion for Refractory Migraine: Angiographic Dose Response and 3‐Month Outcomes

Rami Fakih, Nived Jayaraj Ranjini iD, Syed A Gillani, Kimberley Pfeiffer, Camilo R Gomez, Alexander Sirakov, M Fareed K Suri, Paul Bhogal, Adnan I Qureshi iD

Journal of Neuroimaging · 2025

DOI: 10.1111/jon.70096 ↗

At a glance

Journal article in Journal of Neuroimaging, 2025. Written by Rami Fakih and 8 co-authors. Institution: Centra Medical Group Neurosurgery, Lynchburg, Virginia, USA. Major MEDLINE topics: Lidocaine, Migraine Disorders, Anesthetics, Local, Meningeal Arteries. 20 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Several studies have demonstrated the amelioration of refractory migraines with middle meningeal artery (MMA) intra‐arterial lidocaine infusion, but the durability beyond 1 month is not well studied, and the angiographic dose response of lidocaine infusion was not previously evaluated. We aimed to assess the efficacy of middle meningeal artery lidocaine infusion in the treatment of refractory migraines at a 3‐month follow‐up.

Methods

We quantified the response to intra‐arterial lidocaine infusion (maximum dose of 150 mg) in patients with refractory migraine using the Migraine Disability Assessment (MIDAS) evaluated pre‐ and posttreatment. At 3 months, We determined the MIDAS score changes, the proportion of responders (≥50% MIDAS reduction), the proportion of patients with “no disability” (MIDAS Grade 1), and the cessation of opioid medication for headache management measured at the last known follow‐up. An angiographic dose response was quantified.

Results

Eight patients were included in our analysis (mean age of 49.1 ± 13.2 years; 87.5% were women). The cohort comprised equal numbers of unilateral and bilateral MMA lidocaine infusions (4 each), with doses titrated from 50 to 150 mg per procedure. At 3 months posttreatment, the mean MIDAS score improved from 86.3 ± 40.1 to 23.5 ± 26.8 ( p = 0.001, paired t ‐test), and 62.5% of the patients showed 50% MIDAS score reduction. The disability pre‐treatment was classified as “severe disability” in all patients, and 50% achieved “no disability” (MIDAS Grade 1) at 3 months posttreatment. No adverse events were reported in any of the procedures. At last known follow‐up of a median period of 9.8 months [range 4–21 months], three out of the four patients who were on opioid medication pre‐treatment discontinued their opioid medications following MMA lidocaine infusion.

Conclusion

Intra‐arterial lidocaine infusion was associated with sustained improvement at 3 months posttreatment in 50% of patients with refractory migraines.

Subjects

MeSH terms (MEDLINE)

LidocaineMigraine DisordersAnesthetics, LocalMeningeal ArteriesCerebral AngiographyHumansFemaleMaleMiddle AgedTreatment OutcomeInfusions, Intra-ArterialAdultDose-Response Relationship, Drug

Author keywords

IntraarterialMigraine Disability Assessment (MIDAS)lidocaine infusionmiddle meningeal arterymigrainesrefractory

Substances

LidocaineAnesthetics, Local

Authors and institutions

  • Centra Medical Group Neurosurgery, Lynchburg, Virginia, USA.
  • Department of Neurology, University of Missouri, Columbia, Missouri, USA.
  • Department of Radiology, UH St. Ivan Rilski, Sofia, Bulgaria.
  • Department of Neurology, Aspirus St. Luke's Stroke Center, Duluth, Minnesota, USA.
  • Department of Interventional Neuroradiology, The Royal London Hospital, London, UK.
  • Zeenat Qureshi Stroke Institute, St. Cloud, Minnesota, USA.

ORCID profiles: Nived Jayaraj Ranjini, Adnan I Qureshi

Cite

APA

Fakih, R., Ranjini, N. J., Gillani, S. A., Pfeiffer, K., Gomez, C. R., Sirakov, A., Suri, M. F. K., Bhogal, P., & Qureshi, A. I. (2025). Middle Meningeal Artery Lidocaine Infusion for Refractory Migraine: Angiographic Dose Response and 3‐Month Outcomes. Journal of Neuroimaging. https://doi.org/10.1111/jon.70096

Vancouver

Fakih R, Ranjini NJ, Gillani SA, Pfeiffer K, Gomez CR, Sirakov A, et al. Middle Meningeal Artery Lidocaine Infusion for Refractory Migraine: Angiographic Dose Response and 3‐Month Outcomes. Journal of Neuroimaging. 2025. doi:10.1111/jon.70096

BibTeX
@article{Fakih2025,
  author = {Fakih, Rami and Ranjini, Nived Jayaraj and Gillani, Syed A and Pfeiffer, Kimberley and Gomez, Camilo R and Sirakov, Alexander and Suri, M Fareed K and Bhogal, Paul and Qureshi, Adnan I},
  title = {Middle Meningeal Artery Lidocaine Infusion for Refractory Migraine: Angiographic Dose Response and 3‐Month Outcomes},
  journal = {Journal of Neuroimaging},
  year = {2025},
  doi = {10.1111/jon.70096}
}
Start for free →